Recruiting
Phase 3

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)

Sponsor:

Replimune Inc.

Code:

NCT06264180

Conditions

Advanced Melanoma

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Vusolimogene Oderparepvec

Nivolumab

Nivolumab + Relatlimab

Pembrolizumab

Single-agent chemotherapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information